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Abstract 
Motivation. Atherosclerosis is amongst the leading causes of death globally.  However, it is challeng-
ing to study in vivo or in vitro and no detailed, openly-available computational models exist. Clinical 
studies hint that pharmaceutical therapy may be possible.  Here we develop the first detailed, compu-
tational model of atherosclerosis and use it to develop multi-drug therapeutic hypotheses.  
Results. We assembled a network describing atheroma development from the literature.  Maps and 
mathematical models were produced using the Systems Biology Graphical Notation (SBGN) and Sys-
tems Biology Markup Language (SBML), respectively.  The model was constrained against clinical 
and laboratory data.  We identified five drugs that together potentially reverse advanced atheroma 
formation.   
Availability and Implementation. The map is available in the supplementary information in SBGN-
ML format.  The model is available in the supplementary material and from BioModels, a repository of 
SBML models, containing CellDesigner markup.   
Contact.  s.watterson@ulster.ac.uk 
Supplementary Information.  Available from Bioinformatics online.  
 
 
 
1 Introduction  
Cardiovascular disease (CVD) is the primary cause of global mortali-
ty. CVD is estimated to account for 17.9m deaths worldwide each year, 
representing 31% of all-cause mortality worldwide (WHO, 2018) and 
45% of all-cause mortality within Europe (Wilkins, 2017).  Such a 
prevalent condition incurs a significant financial burden, accounting for 
17% of all healthcare expenditure in the USA.  Age is a significant risk 
factor and with an aging population, the cost of CVD related therapies is 
predicted to almost triple in the USA from $273 billion in 2010 to $818 
billion by 2030 (Heidenreich, 2011).  
Atherosclerosis is estimated to account for 71% of CVD diagnoses 
(Nichols, 2012).  It is characterized by the hardening of an artery wall, 
and the formation of a fibrous-fatty lesion within the surface layer.  As 
the disorder progresses, thick extracellular plaques of lipid build within 
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the artery wall, occluding the artery and reducing blood flow.  Either as a 
result of plaque rupture or of the turbulent blood flow they induce, 
thrombosis can occur, further occluding the artery (Insull Jr, 2009; Par-
ton, 2016). 
Despite our increasing knowledge of the mechanisms involved in this 
disorder, its formation is still not fully understood.  In part, this is due to 
the significant challenge inherent in studying live, dynamic plaques.  
Accessing plaques in vivo is logistically difficult, necessitating catheteri-
zation, and ethically challenging as it can increase the risk of plaque 
rupture.  As a result, alternative approaches to studying the dynamics of 
atherosclerosis are needed.  Computational modelling has the potential to 
be especially valuable here due to its flexibility, low financial and ethical 
cost, consistency and ease of replication.  However, currently there are 
no computational or mathematical models of atherosclerosis that capture 
the molecular biology involved and are available to the research commu-
nity for use in exploratory studies.   
The molecular and cellular biology that mediates plaque formation 
can furnish drug targets for therapy development.  Previous studies have 
typically focused on blood flow and plaque initiation (Parton, 2016; Di 
Tomaso, 2011; Silva, 2013) routinely omitting or simplifying details of 
the molecular and cellular biology for reasons of mathematical expedi-
ency (Bulelzai, 2012; Friedman, 2015; El Khatib, 2009).  Critically, the 
resulting models have not been made publicly available with only one 
model pertaining to atheroma formation presently in the BioModels 
database (Chelliah, 2015), focusing on lipoprotein action and B-cell 
signaling with little detail on the mechanisms of plaque formation 
(Gomez-Cabrero, 2011). KEGG (Kanehisa, 2017), Reactome (Fabregat, 
2016) and Wikipathways (Kutmon, 2011) contain no molecular biology 
maps of atherosclerosis.  However models of contributory factors such as 
cholesterol metabolism do exist (Mazein, 2013; Watterson, 2013). 
Here we develop the first detailed, predictive dynamical computation-
al model of the formation of atherosclerosis using Systems Biology 
standards.  The model is mapped using the Systems Biology Graphical 
Notation (SBGN) (Le Novere, 2009) and made available to the research 
community for reuse and refinement using the Systems Biology Graph-
ical Notation Markup Language (SBGN-ML) (van Iersel, 2012).  This 
map is accompanied by a mathematical model describing the dynamics 
of the interactions in the map as a system of ordinary differential equa-
tions (ODEs), made available using the Systems Biology Markup Lan-
guage (SBML) (Hucka, 2003) and compatible with CellDesigner (Fu-
nahashi, 2008).  There are many examples of SBGN and SBML compli-
ant software (see http://sbgn.github.io/sbgn/software_support and 
http://sbml.org/SBML_Software_Guide respectively). 
Currently, treatment of atherosclerosis focuses on limiting disease 
progression (though smoking cessation, lipid lowering, and anti-platelet 
therapies and optimal management of hypertension and diabetes) and 
revascularization procedures such as angioplasty and bypass grafting to 
clinically relevant stenotic lesions in the vasculature. Such treatments are 
clinically effective in managing patient risk.  It is less clear whether 
therapies can reduce plaque size, although there is some evidence to 
suggest that intense statin treatment (Lima, 2004), combined statin-
PCSK9 inhibitor treatment (Nicholls, 2016) or Cyclodextrin treatment 
(Zimmer, 2016) may yield a modest plaque reduction.  New therapies 
that yield a substantial reduction in plaque size could have a dramatic 
impact on CVD morbidity and mortality and so their identification has 
high strategic importance.  Here, we employ the model to develop effec-
tive therapeutic strategies comprising multi-drug combinations that re-
program disease dynamics leading to plaque regression.   
2 Methods 
A list of the cell types involved in atherosclerosis was compiled from 
the existing literature (see supplementary table S4).  Each article identi-
fied was also searched for references to proteins and small molecules 
with each entity found considered for the model.  A protein or small 
molecule was incorporated if its biological source, presence within a 
compartment and influence on atherogenesis (however minor) were all 
described. The model was assembled with CellDesigner (Funahashi, 
2008) using SBGN with mass action and Michaelis-Menten equations 
primarily used to describe the dynamics.  The resulting model was ex-
ported to SBGN-ML file format to disseminate the visual map and to 
SBML file format to disseminate the mathematical model. It was subse-
quently analysed using MATLAB software 
(https://www.mathworks.com). 
We considered dynamics for three lipid profiles: high risk, medium-
risk and low-risk comprising LDL concentrations of 190 mg/dl, 110 
mg/dl (https://www.nhlbi.nih.gov/health/resources/heart/heart-
cholesterol-hbc-what-html) and 50mg/dl (O'Keefe, 2004), respectively 
and HDL concentrations of 40 mg/dl, 50 mg/dl and 50 mg/dl, respective-
ly (Boden, 2000).  Atherosclerosis is considered to be a chronic condi-
tion.  Hence, we considered plaque formation across a representative 
time scale of 80 years.  The BRENDA enzyme database was searched 
for relevant known rate parameters (Placzek, 2017).  In order to con-
strain parameters with unknown values, PubMed and Google Scholar 
searches were undertaken to find studies describing representative con-
centrations of the cells, proteins and small molecules involved.  This 
enabled us to compile a series of clinical observations.  Unknown pa-
rameters were optimized so as to maximize the agreement between the 
behavior of the model and these observations (see tables 1 and 2).   
There are between 5 and 800 cells within a plaque area per high pow-
ered field (HPF) at 400x magnification (Brandl, 1997), where one HPF 
displays approximately 0.2mm2 of plaque area (Bonanno, 2000).  We 
estimate that a plaque contains between 25 and 4000 cells per mm2. 
Average plaque area has been shown to be 15.2mm2 (von Birgelen, 
1998), giving the number of cells in a plaque as being between 380 and 
60800.  Using this result and the references shown, we identified the 
quantitative and qualitative constraints outlined in tables 1 and 2. 
The model was replicated in MATLAB and simulated using the non-
stiff differential equation solver function ‘ode23t’. To ensure accurate 
replication, the SBML version of the model was also simulated using the 
SBML ODE Solver built into CellDesigner.  Initial conditions for each 
entity were estimated using control group data in cardiovascular disease 
studies (see supplementary table S3). Concentrations of LDL and HDL 
in the blood were kept constant, to reflect a stable patient context.  
The resulting model contains 89 ordinary differential equations 
(ODEs), which are detailed in supplementary table S1. 
2.1 Multi-drug plaque regression therapeutic hypotheses 
To demonstrate the utility of the model, we undertook to identify an 
optimal multi-drug intervention hypothesis that would reprogram the 
dynamics of the model leading to regression of advanced plaques.  It has 
been demonstrated that multidrug approaches have the potential to ex-
ploit compound effects to yield effective interventions at lower individu-
al and collective dosages than in comparable single-drug interventions, 
reducing the risk from pleotropic effects (Benson, 2017).  This is an 
example of the type of investigation that would be highly challenging to 
undertake in vivo yet can be undertaken computationally with ease. 
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We identified the following 9 drugs with targets in the model (targets 
in brackets): 2-(4-Chloro-3-(trifluoromethyl)phenoxy)-5-(((1-methyl-6-
morpholino-2-oxo-1,2-dihydropyrimidin-4-yl)oxy)methyl)benzonitrile  
  
Figure 1. A map of atherosclerotic plaque dynamics shown using the Systems Biology Graphical Notation (SBGN). 
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(PLA2), GW4869 (SMase), Quercetin Monoglucoside (Lipoxygen-
ase), cFMS Receptor Inhibitor III (MCSF), Bindarit (CCL2), Imatinib 
Mesylate (PDGF), Ustekinumab (IL12R), GSK1070806 (IL18R), 
SCH546738 (CXCL9, CXCL10, CXCL11, CCL5).  Because PLA2, 
SMase and Lipoxygenase all catalyse the same interaction, we con-
strained these drugs to have the same concentration, giving a set of drugs 
with seven degrees of freedom.  
We identified the optimal combination of drugs that would drive ath-
erosclerosis regression using a genetic algorithm and a bespoke scoring 
function (see supplementary section S1) in MATLAB.  A genetic algo-
rithm was chosen for its ease of parallelisation and the transparency of its 
convergence.  The analysis was run on an Intel(R) Xeon(R) CPU E5-
2630 v3 @ 2.6GHz (Octo-core) CPU with 64GB of RAM running Cen-
tOS 7.   
3 Results 
A map of the model obtained is shown in Figure 1 using the SBGN 
schema.  The model covers the liver, intestine, lumen, endothelium and 
tunica intima, including LDL retention, LDL oxidation, monocyte re-
cruitment, monocyte differentiation, smooth muscle cell proliferation, 
phagocytosis, reverse cholesterol transport and T-cell proliferation.  The 
cell types involved include monocytes, endothelial cells, T-cells, macro-
phages, foam cells, B-cells, smooth muscle cells, neutrophils, dendritic 
cells and mast cells.  Each interaction represents a parameterized equa-
tion (see supplementary tables S1 and S2), enabling us to simulate the 
changing concentrations/abundances of the model as the plaque forms.   
The initial conditions identified are described in supplementary table 
S3 and unknown parameters were optimized so that the model simulta-
neously satisfied the constraints described in tables 1 and 2.  Along with 
figures S2, S3 and S4, tables 1 and 2 demonstrate consistency with the 
underlying unperturbed biology.   Key markers for plaque development 
include smooth muscle cell, macrophage and foam cell and Th1 cell 
proliferation.  Their behavior for the three risk profiles is shown in Fig-
ure 2.  
3.1 Reusability of the model 
The files can be opened, edited and analyzed in software supporting the 
SBGN-ML and SBML standards.  SBML compliant software includes 
Copasi (Bergmann, 2017), Cytoscape with the cy3SBML plugin (König, 
2012) and Dizzy (Ramsey, 2005).  Supplementary Fig S1 shows the 
graphical map opened in three representative SBGN compliant editors: 
Newt (http://web.newteditor.org/), PathVisio (Kutmon, 2015) and 
VANTED with SBGN-ED extension (Czauderna, 2010) along with a 
subsection of the plain text, XML file.   
3.2 Therapeutic hypothesis generation 
We determined the following drug combination that optimally drove 
plaque regression.  Concentrations are described as multiples of the 
corresponding inhibition constants, ki. 2-(4-Chloro-3-
(trifluoromethyl)phenoxy)-5-(((1-methyl-6-morpholino-2-oxo-1,2-
dihydropyrimidin-4-yl)oxy)methyl)benzonitrile (PLA2) – 4.35x10-5, 
GW4869 (SMase) – 4.35x10-5, Quercetin Monoglucoside (Lipoxygen-
ase) – 4.35x10-5, Bindarit (CCL2) – 37.0, cFMS Receptor Inhibitor III 
(MCSF) – 0, SCH546738 (CXCL9, CXCL10, CXCL11, CCL5) – 
8.45x10-4, Ustekinumab (IL12R) – 7.62, GSK1070806 (IL18R) – 7.60, 
Imatinib Mesylate (PDGF) – 0.  As can be seen from Fig 3A, this com-
bination was identified quickly with approximately optimal results being 
identified within 20 generations using a genetic algorithm.  Figs 3B, 3C 
and 3D show the predicted dynamics of atherosclerosis after this inter-
vention is applied at forty years following forty years of the high risk 
lipid profile.  We can see that smooth muscle cells, macrophages and 
foam cells and Th1-cell counts are all rapidly driven down by the inter-
vention.   
4 Discussion 
CVD is a large burden on healthcare worldwide.  Front line therapies for 
the primary and secondary prevention of atherosclerotic disease include 
smoking cessation, lipid management, blood pressure control, optimal 
control of diabetes and the use of antiplatelet agents.  However, the 
Figure 2.  Key indicators of plaque formation during plaque development 
for the three blood LDL/HDL profiles: 190/40 mg/dl, 110/50 mg/dl and 
50/50 mg/dl.  (A) Smooth muscle cell concentrations.  (B) macrophage 
and foam cell concentrations.   (C) Th1 cell concentrations  
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number of pharmaceutical therapies is limited. By far the most common-
ly used  
class of lipid lowering drugs is statins, which inhibit HMG-CoA reduc-
tase. Ezetimibe, a cholesterol absorption inhibitor, may be used in pa-
tients who are statin intolerant or who do not achieve lipid targets on the 
highest maximally targeted dose of statin. A new, recently licenced class 
of drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibi-
tors, suppress degradation of LDLR by PCSK9 and are associated with a 
significant reduction in serum LDL concentration and in cardiovascular 
events. Emerging drugs include Apolipoprotein B antisense drugs that 
suppress translation of ApoB, a key component of LDL, and microsomal 
triglyceride transfer protein inhibitors that induce significant LDL reduc-
tion (Henderson, 2016). 
Atherosclerotic plaques are highly challenging to study due to their 
location.  In vivo study presents logistical and ethical challenges and 
there are few in vitro resources.  Whilst they are not a replacement for in 
vivo studies, computational studies have the potential to contribute non-
in vivo resources that can improve our understanding of CVD.  
Here we have produced the first detailed, predictive model of athero-
sclerosis pathophysiology and it can serve as a resource for the research 
community to be reused, refined and expanded in future.  Models of this 
type can be used to predict the on-target and off-target consequences of 
interventions.  This can be exploited in single drug development to iden-
tify the drug targets that have the greatest potential therapeutic value or 
in multi-drug intervention development to identify drug combinations 
and target combinations with the greatest potential therapeutic value 
(Benson, 2017).  The scale of the global CVD burden means that there is 
a pressing need to develop new pharmaceutical therapeutics that both 
address clinical need and can sustain the pharmaceutical industry as 
intellectual property protection expires around current therapeutics.  
Multi-drug interventions of the type identified here have a vast untapped 
potential to contribute to future therapeutics in this way.   
The development of therapeutic hypotheses can form part of pro-
grammes of personalized or stratified medicine by adapting the parame-
ters to individuals or to patient subgroups. Such parameterizations could 
be identified by optimizing the model to time course data or by determin-
ing the impact of single nucleotide polymorphisms on protein function. 
The dynamics of the model show broad agreement with observed clin-
ical results (see tables 1 and 2).  Because the model describes spatial 
effects and cellular function very simply, it is unlikely to be able to rec-
reate all clinical results exactly.  Doing so would require greater com-
plexity across length scales.  However, we demonstrate order of magni-
tude agreement in almost all cases and show the correct qualitative dose 
responses.  Optimizing the parameters so as to ensure a sufficiently large 
response to changes in lipoprotein profile for particular model compo-
nents was challenging.  Consequently, particular components are sys-
tematically over-estimated for the low LDL profile and the difference 
between high and low LDL profiles, although large, is not as great as 
that observed clinically.  In changing the lipid profile, we adjusted the 
concentrations of LDL and HDL in the model.  This logically does not 
impact upon components upstream of LDL and HDL.  Hence, we would 
expect to see no resulting change in chylomicron or triglyceride concen-
trations as described in rows 28 and 29 of table 1.  To see changes in 
chylomicron or triglyceride concentrations would require either modify-
ing VLDL and IDL values across risk profiles or incorporating further 
feedback into the model. 
Atherosclerosis is known to have comorbidities such as rheumatoid 
arthritis and depression (Gibson, 2017).  By using incorporating ‘omic 
data from studies of other diseases, this model can be used to explore 
their impact on atherosclerosis as a comorbidity.  Similarly, it can be 
used to explore the impact of therapies for other diseases on atheroscle-
rosis either where there are targets in atherosclerosis associated pathways 
or through changes to ‘omic profiles.   
The therapeutic hypotheses identified here could be validated and de-
veloped further by experimentation in animal models (Getz, 2012).  Each 
animal model has limitations and none are a perfect surrogate for human 
atheroma.  As a result, the computational model presented here would 
need to be adapted for each animal system and new therapeutic hypothe-
ses would need to be generated.  However, this would be the next step 
towards therapy development. 
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Quantitative Comparison From literature From model 
No Measureable Location Units Estimate source Lower 
estimate 
Upper 
estimate  
Sole 
estimate 
Lower 
prediction 
Upper 
prediction 
Sole predic-
tion 
Figure 
1 Smooth muscle cell 
count 
Plaque cells 35.10% of cellular composition (Bonanno, 2000) 133 21341  230 42287  2A 
2 Macrophage (including 
foam cell) count 
Plaque cells 34.07% of cellular composition (Bonanno, 2000) 129 20715  3463 27630  2B 
3 Th1 cell count Plaque cells Ratio of Th1 to non-Th1 cells approximately 0.3 
(van Dijk, 2015) 
88  14031  223 7186  2C 
4 MCP1/CCL2 concen-
tration 
Blood 
serum 
pg/ml myocardial infarction and ischemic stroke patients 
(Arakelyan, 2005) 
100  775  163.8 649.8  S2.1 
5 CXCL9 concentration Blood 
serum 
pg/ml patients assessed for coronary artery calcium depos-
its (Yu, 2015) 
17.4  271.2  23.8 283.9  S2.2 
6 CXCL10 concentration Blood 
serum 
pg/ml patients assessed for coronary artery disease 
(Ferdousie, 2017) 
127.6  956.5  120.9 850.0  S2.3 
7 CXCL11 concentration Blood 
serum 
pg/ml control groups in transplantation studies (Kao, 2003) 420  1062  355 965  S2.4 
8 IL1b concentration Blood 
serum 
pg/ml congestive heart failure and control patients (Di 
Iorio, 2003) 
0.28  2.12  0.97 2.04   S2.5 
9 TIMP1 concentration Plaque μg/g carotid endarterectomy patients, per wet weight 
plaque (Molloy, 2004) 
5.3  12.4  3.6 11.5  S2.6 
10 IFNg concentration Plaque pg/g carotid endarterectomy patients, per wet weight 
plaque (Grufman, 2004) 
20  182  5 167  S2.7 
11 TGFb concentration Plaque mg/g control and coronary artery disease patients, per 
weight protein (Herder, 2012) 
0.33  0.76  0.05 0.80  S2.8 
12 Chymase to tryptase 
density ratio 
Plaque none (Ramalho, 2013)   107.8:135
.1 
  106.0:134.3 
high risk 
profile. 
S2.9 
13 T cell count Plaque cells 30.82% of cellular composition (Bonanno, 2000) 117  18739  8012  18562  S2.10 
14 CCL5 concentration Blood 
serum 
ng/ml control and coronary event patients (Herder, 2011) 2.7  176.0  45.7 181.1  S2.11 
15 MMP1 concentration Plaque ng/g carotid endarterectomy patients, per wet weight 
plaque (Molloy, 2004) 
18  104  0.2  86.8  S2.12 
16 MMP9 concentration Plaque ng/g carotid endarterectomy patients, per wet weight 
plaque (Molloy, 2004) 
121  722  1.6 609.6  S2.13 
17 IL1b concentration Plaque ng/g carotid endarterectomy patients, per wet weight 
plaque (Molloy, 2004)  
12  24  0.1 23.6  S2.14 
18 IL6 concentration Plaque μg/g carotid endarterectomy patients, per wet weight 
plaque (Molloy, 2004)  
1.5  5.1  0.025 5.3  S2.15 
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19 TNFa concentration Plaque ng/g carotid endarterectomy patients, per wet weight 
plaque (Molloy, 2004) 
15  27  0.3 24  S3.1 
20 IL10 concentration Plaque ng/g arterial occlusion patients, ranging per wet weight 
plaque (Stein, 2008) 
1.51  2.29  0.6 2.1  S3.2 
21 IL12 concentration Plaque ng/g arterial occlusion patients, per wet weight plaque 
(Stein, 2008) 
3.6  4.6  0.7 5.2  S3.3 
22 Elastin concentration Plaque mg/g acute coronary syndrome patients, per wet weight 
plaque (Gonçalves, 2003) 
  1.58    1.85 high 
risk profile 
S3.4 
23 Collagen concentration Plaque  mg/g acute coronary syndrome patients, per wet weight 
plaque (Gonçalves, 2003) 
  6.26    4.87 high 
risk profile. 
S3.5 
24 PDGF concentration Plaque pg/g carotid endarterectomy patients, per wet weight 
plaque (Grufman, 2004) 
279  1381  2 1048  S3.6 
25 Oxidized LDL concen-
tration 
Plaque μg/g weight of oxidized LDL per weight ApoB is 19.6 
ng/μg in plaques and 1.9 ng/μg in normal intimal 
tissue (Nishi, 2002).  Plaque concentration of ApoB 
ranges from 1.97 μg/mg to 0.13 μg/mg (Hoff, 1978) 
0.25  38.6  2.6 36.8   S3.7 
26 IL2 concentration Plaque ng/g acute coronary syndrome patients, per weight protein 
(Ragino, 2012) 
  24.0    27 high risk 
profile 
S3.8 
27 IL18 concentration Plaque ng/g acute coronary syndrome patients, per weight protein 
(Ragino, 2012) 
  10.7    10.9 high 
risk profile 
S3.9 
28 Chylomicron concen-
tration 
Blood 
serum 
μg/ml control and hyperlipidemic patients (Sakai, 2003) 1.4  52.6  49.1l 49.1  S3.10 
29 Triglyceride concen-
tration 
Blood 
serum 
mg/dl control and hyperlipidemic patients (Sakai, 2003) 58  1005   754  754l  S3.11 
 
 
 
 
  
 
Table 1:  Quantitative constraints applied to the model. 
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Qualitative comparison From literature From model 
No Measureable Location Estimate source Predicted behaviour Figure 
30 Atherogenic cell 
count  
Plaque Ratio of Th1 to Th2 cell count 
correlates with atherogenesis 
(Szodoray, 2006) 
For high risk profile, increasing rate 
parameter of differentiation to Th1 
cells by 10% and decreasing rate 
parameter of differentiation to Th2 
cells by 10% increases foam cell 
counts.   
S3.12 
31 Atherogenic cell 
counts 
Plaque Animal models show plaque 
reduction mediated by reverse 
cholesterol transport after 
reducing lipid profile (Trogan, 
2006) 
Oxidized LDL concentration, smooth 
muscle cell count and foam cell count 
reduce when high risk profile 
switched to low risk profile. 
S3.13, 
S3.14, 
S3.15 
32 Atherogenic cell 
counts 
Plaque Blocking endogenous IL-12 
has been shown to reduce 
atherogenesis (Hauer, 2005) 
Reducing the rate parameter for IL-12 
production by 75%, reduces foam cell 
count. 
S4.1 
33 Atherogenic cell 
counts 
Plaque Deficiency of ABCA1 func-
tion impairs reverse cholester-
ol transport, increases athero-
ma size (Westerterp, 2013) 
Reducing the initial ABCA1 concen-
tration by 90%, increases foam cell 
concentration. 
S4.2 
34 Macrophage and 
monocyte cell count 
Plaque Deficiency of MCSF reduces 
monocyte/macrophage circu-
lation, plaque formation (Qi-
ao, 1997) 
Reducing the initial MCSF concentra-
tions from 100 mg/g of tissue to 0 
reduces macrophage count. 
S4.3 
35 T cell count Plaque IFNGR knockout reduces T-
cells abundance (Gupta, 1997) 
Decreasing the rate parameter for 
IFNG production by 50% reduces T-
cell abundance. 
S4.4 
36 Atherogenic cell 
count 
Plaque IL-18 increases are atherogen-
ic (Whitman, 2002) 
Increasing the rate parameter for IL-
18 production by 50%, increases 
smooth muscle cell recruitment. 
S4.5 
37 Oxidized LDL 
concentration 
Plaque Reducing proteoglycan con-
centration reduces intimal 
oxLDL concentrations (Del-
gado-Roche, 2015) 
Decreasing the initial concentration 
of proteoglycan concentration from 
500 to 100 mg/g of tissue reduces 
oxidized LDL concentration. 
S4.6 
38 Collagen concentra-
tion 
Plaque Increasing matrix metallopro-
teinase activity leads to de-
graded extracellular matrix 
(Adiguzel, 2009) 
Doubling the rate parameter for bind-
ing between extra cellular matrix and 
matrix metalloproteinases reduces 
collagen concentrations. 
S4.7 
39 Atherogenic cell 
count 
Plaque PLA2 concentration correlates 
with atherogenesis (Vickers, 
2009) 
Reducing initial PLA2 concentration 
by 90% reduces foam cell count. 
S4.8 
40 Smooth muscle cell 
count 
Plaque Increasing PDGF activity 
increases smooth muscle cell 
abundance (Ferns, 1991) 
Increasing the rate parameter for 
PGDF production by 200% increases 
smooth muscle cell recruitment.  
S4.9 
 
Table 2: Qualitative constraints applied to the model.  
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